Kingdon Capital Management, L.L.C. Akero Therapeutics, Inc. Transaction History
Kingdon Capital Management, L.L.C.
- $834 Million
- Q3 2024
A detailed history of Kingdon Capital Management, L.L.C. transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Kingdon Capital Management, L.L.C. holds 79,500 shares of AKRO stock, worth $4.31 Million. This represents 0.47% of its overall portfolio holdings.
Number of Shares
79,500Holding current value
$4.31 Million% of portfolio
0.47%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding AKRO
# of Institutions
194Shares Held
74.8MCall Options Held
241KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.9MShares$428 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$384 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$321 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$303 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$284 Million5.21% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.52B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...